A Randomized Phase 2/3 Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
Status: Recruiting
Location: See all (7) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 18 years and older
• ECOG 0-1
• Life expectancy ≥ 6 months
• Histologically documented unresectable LA/mUC (transitional cell carcinoma) of the bladder, renal pelvis, ureter, or urethra with ≥50% urothelial carcinoma component
• No prior systemic therapy for LA/mUC
• At least one measurable non-cerebral lesion according to RECIST v1.1
• Adequate organ function
Locations
United States
Arizona
Research Site
NOT_YET_RECRUITING
Phoenix
California
Research Site
RECRUITING
Los Angeles
Washington, D.c.
Research Site
NOT_YET_RECRUITING
Washington D.c.
Florida
Research Site
NOT_YET_RECRUITING
Jacksonville
Minnesota
Research Site
NOT_YET_RECRUITING
Rochester
Tennessee
Research Site
NOT_YET_RECRUITING
Nashville
Washington
Research Site
RECRUITING
Spokane
Contact Information
Primary
Summit Clinical Trial Information
medicalinformation@smmttx.com
1-833-256-0522
Time Frame
Start Date: 2026-09-10
Estimated Completion Date: 2030-12-31
Participants
Target number of participants: 800
Treatments
Experimental: Phase 2: Arm A
Ivonescimab Dose 1 + EV
Experimental: Phase 2: Arm B
Ivonescimab Dose 2 + EV
Experimental: Phase 3: Arm 1
Ivonescimab RP3D (recommended Phase 3 dose) + EV
Active_comparator: Phase 3: Arm 2
Pembrolizumab 200 mg + EV
Related Therapeutic Areas
Sponsors
Leads: Summit Therapeutics